January 8, 2018
Calgene Corp buys Impact Biomedicines for $2,3 billion
Celgene Corporation and Impact Biomedicines have agreed for Celgene to acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and…
Pharmaceuticals, Biotechnology and Life Sciences
Celgene Corporation and Impact Biomedicines have agreed for Celgene to acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and…
Juno Therapeutics, a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, and Celgene Corporation have additional data from the…
UBM EMEA’s Pharmapack Europe 2017 has named the winners of the 2017 Pharmapack Awards on Wednesday, picking four innovations in the Exhibitor Innovation category, while two winners were chosen to get awards in the Health Product category.